Ribociclib&Belinostat In Patients w Metastatic Triple Neg Breast Cancer & Recurrent Ovarian Cancer w Response Prediction By Genomics

PHASE1RecruitingINTERVENTIONAL
Enrollment

34

Participants

Timeline

Start Date

May 3, 2021

Primary Completion Date

June 30, 2025

Study Completion Date

August 31, 2026

Conditions
Metastatic Breast CancerRecurrent Ovarian Carcinoma
Interventions
DRUG

Ribociclib

Ribociclib Dose Level 0 (starting dose) 200mg QD Dose Level 1A 400mg QD on Days 8-28 Dose Level 1B 200mg QD Dose Level 2 400mg QD on Days 8-28

DRUG

Belinostat

"Belinostat Dose Level 0 (starting dose) 600mg/m2 daily for 5 days Dose Level 1A 600mg/m2 daily for 5 days Dose Level 1B 1000mg/m2 daily for 5 days Dose Level 2 1000mg/m2 daily for 5 days~\*Administration on 5 consecutive days is preferred. Administration within 7 days allowed as needed to accommodate holidays and infusion schedules."

Trial Locations (2)

22031

RECRUITING

Inova Schar Cancer Institute, Fairfax

84112

RECRUITING

Huntsman Cancer Institute, Salt Lake City

Sponsors
All Listed Sponsors
collaborator

Novartis

INDUSTRY

collaborator

Acrotech Biopharma

UNKNOWN

lead

University of Utah

OTHER